EPO Publishes: “New Frontiers in Oncology: An Evolving Innovation Ecosystem”

Last week, on the eve of World Cancer Day, the European Patent Office (EPO) published a new study that shows wide variations between leading countries in the profiles of startups for new diagnostic and therapeutic technologies. 

The study provides an unprecedented level of detail on the varying development rates of emerging technologies for cancer detection and treatment. "New Frontiers in Oncology: An Evolving Innovation Ecosystem" highlights the most promising advancements and examines regional, sectoral, and institutional differences. This insight helps policymakers, researchers, clinicians, entrepreneurs, and industry stakeholders refine their strategies for policy-making, research, and investment.

The study reveals that nearly 1,500 start-ups operate within the 39 member states of the EPO surpassing the 1,325 start-ups in the US. Within Europe, the UK leads with 290 startups, followed by France with 246 and Germany with 208. While Europe boasts a higher number of start-ups in the seed and early growth phases, the US sees a significantly larger share of start-ups successfully scaling up to the late growth stage.

Read the full study.